Clinical Trials | December 23, 2025
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
NUFYMCO BLA has been approved by the USFDA
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Hansoh Pharma will receive an upfront payment in the low double-digit millions
India plays a critical role in Bristol Myers Squibb’s global strategy
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
Subscribe To Our Newsletter & Stay Updated
